会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 9. 发明申请
    • SCREENING FOR SYNERGISTIC COMPOUNDS
    • 筛选合成化合物
    • WO2005051303A2
    • 2005-06-09
    • PCT/US2004/039086
    • 2004-11-19
    • ZHANG, Lixin
    • ZHANG, Lixin
    • A61K
    • A61K31/00A61K31/496A61K31/70G01N33/94A61K2300/00
    • This invention provides a powerful systematic approach to discovering next generation of chemical compounds or formulation that acts synergistically with the low dosage of known drugs. Existing drug or dropped drug candidate is selected. Then a library of either natural products or synthetic chemicals (pure or combinatorial) including macromolecules like nucleic acids and proteins is created. A functional assay including biochemical, cell based assays, animal models or clinical treatments are established, and a sub-optimal dose (10 % - 40 % of the maximum activity) of the selected drug is determined. Under this condition, the library at different titration would be screened in a high throughput manner that should give a 0.1 % to 1 % hit rate. The synergistic co-drug hit should generate 70 % - 100 % of the maximum activity by combination with the sub-optimal concentration of existing drug. Finally, the co-drug hits would be purified and identified. The co-drug could be a pure synthetic molecule, a compound from a combinatorial synthetic library or a mixture from nature or synthetic resources.
    • 本发明提供了一种强有力的系统方法来发现与低剂量的已知药物协同作用的下一代化合物或制剂。 选择现有药物或药物候选药物。 然后创建包括大分子如核酸和蛋白质的天然产物或合成化学品(纯或组合)的文库。 建立了包括生物化学,基于细胞的测定,动物模型或临床治疗的功能测定,并确定所选药物的次优剂量(最大活性的10%-40%)。 在这种情况下,不同滴定的文库将以高通量的方式进行筛选,这样可以得到0.1%至1%的命中率。 通过与现有药物的次优浓度组合,协同共同药物的攻击应产生70%〜100%的最大活性。 最后,共同药物的命中将被纯化和鉴定。 共同药物可以是纯合成分子,来自组合合成文库的化合物或来自天然或合成资源的混合物。